Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study |
| |
| Authors: | Robert Bain Rebecca Cosgriff Marco Zampoli Alexander Elbert Pierre-Régis Burgel Siobhán B Carr Claudio Castaños Carla Colombo Harriet Corvol Albert Faro Christopher H Goss Hector Gutierrez Andreas Jung Nataliya Kashirskaya Bruce C Marshall Joel Melo Pedro Mondejar-Lopez Isabelle de Monestrol Malcolm Brodlie |
| |
| Affiliation: | 1. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom;2. Cystic Fibrosis Trust, London, United Kingdom;3. Division of Paediatric Pulmonology, Department of Paediatrics and Child Health, Red Cross War Memorial Children''s Hospital, University of Cape Town, South Africa;4. Cystic Fibrosis Foundation, Bethesda, MD, United States;5. Respiratory Medicine and National Reference CF Center, AP-HP Hôpital Cochin, Paris, France;6. Université de Paris, Institut Cochin, Inserm U-1016, Paris, France;7. Royal Brompton Hospital and Imperial College London, United Kingdom;8. Department of Pulmonology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina;9. CF Regional Reference Center, Fondazione IRCCS Ca'' Granda Ospedale Maggiore Policlinico, University of Milan, Italy;10. Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France;11. Department of Medicine and Pediatrics, University of Washington, Seattle, WA, United States;12. Pediatric Pulmonary and Sleep Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States;13. Department of Pulmonology and Children''s Research Centre, University Children''s Hospital Zurich, Zurich, Switzerland;14. Laboratory of Genetic Epidemiology, Research Centre for Medical Genetics, Moscow, Russian Federation;15. Instituo Nacional del Tórax, Santiago, Chile;p. Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain;q. Stockholm Cystic Fibrosis Centre Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden;r. Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus‐Liebig‐University Giessen, Giessen, Germany;s. Pediatric Pulmonology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Barakado, Bizkaia, Spain;t. Pediatric Pulmonology Unit, Instituto da Criança do Hospital das Clínicas da FMUSP, São Paulo, São Paulo, Brazil;u. Paediatric Respiratory Medicine, Great North Children''s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom;v. Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy;w. National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit Istituto Superiore di Sanità, Rome, Italy |
| |
| Abstract: | BackgroundThe presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams.MethodsCases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020.ResultsData on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6–15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79–104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease.ConclusionsSARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
